Overview
Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome is an extremely rare genetic neurological condition that affects the brain and nervous system from a young age. The disease is caused by mutations in specific genes that disrupt normal nerve function. People with this condition typically develop a combination of problems including spasticity (stiffness and tightness in the muscles, especially in the legs), ataxia (difficulty with balance and coordination), myoclonic epilepsy (seizures that involve sudden, brief muscle jerks), and peripheral neuropathy (damage to the nerves outside the brain and spinal cord, causing numbness, tingling, or weakness in the hands and feet). Symptoms usually begin in childhood and tend to worsen over time. Walking becomes increasingly difficult due to the combination of stiff muscles, poor balance, and nerve damage. The seizures can vary in severity and may be difficult to control with standard medications. Because this syndrome affects multiple parts of the nervous system, patients often need care from several different specialists. Treatment is currently focused on managing individual symptoms, as there is no cure available. Anti-epileptic medications are used to control seizures, physical therapy helps maintain mobility, and other supportive treatments address specific symptoms as they arise.
Also known as:
Key symptoms:
Muscle stiffness and tightness, especially in the legsPoor balance and coordinationSeizures with sudden muscle jerks (myoclonic epilepsy)Numbness or tingling in hands and feetWeakness in the arms and legsDifficulty walkingUnsteady gaitMuscle wasting over timeDifficulty with fine motor tasks like writingSpeech difficultiesReduced reflexes in the limbsProgressive loss of mobility
Clinical phenotype terms (24)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome.
Community
No community posts yet. Be the first to share your experience with Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome.
Start the conversation →Latest news about Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome
No recent news articles for Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What specific gene mutation is causing this condition in my case, and what does that mean for disease progression?,Which anti-epileptic medications are most appropriate, and what side effects should I watch for?,How often should we have follow-up neurological evaluations and EEGs?,What physical therapy program would be most beneficial to maintain mobility?,Are there any clinical trials or research studies we could participate in?,What is the risk that other family members or future children could have this condition?,What emergency plan should we have in place for seizures?
Common questions about Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome
What is Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome?
Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome is an extremely rare genetic neurological condition that affects the brain and nervous system from a young age. The disease is caused by mutations in specific genes that disrupt normal nerve function. People with this condition typically develop a combination of problems including spasticity (stiffness and tightness in the muscles, especially in the legs), ataxia (difficulty with balance and coordination), myoclonic epilepsy (seizures that involve sudden, brief muscle jerks), and peripheral neuropathy (damage to the nerves outsi
How is Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome inherited?
Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome typically begin?
Typical onset of Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome is childhood. Age of onset can vary across affected individuals.